AFP and hepatocellular carcinoma: Currently, multiple systemic therapeutic options are FDA approved as second line agents for advanced HCC including cabozantinib [9], regorafenib [10], ramucirumab (for alpha-fetoprotein (AFP) >400 mg/mL) [11], and pembrolizumab [12,13,14].